journal
Journals European Journal of Clinical P...

European Journal of Clinical Pharmacology

https://read.qxmd.com/read/38498098/population-pharmacokinetic-analyses-of-methotrexate-in-pediatric-patients-a-systematic-review
#21
REVIEW
Yu Cheng, Yujia Zhang, Ying Zhang, Maobai Liu, Limei Zhao
BACKGROUND AND OBJECTIVES: Methotrexate is widely utilized in the chemotherapy of malignant tumors and autoimmune diseases in the pediatric population, but dosing can be challenging. Several population pharmacokinetic models were developed to characterize factors influencing variability and improve individualization of dosing regimens. However, significant covariates included varied across studies. The primary objective of this review was to summarize and discuss population pharmacokinetic models of methotrexate and covariates that influence pharmacokinetic variability in pediatric patients...
March 18, 2024: European Journal of Clinical Pharmacology
https://read.qxmd.com/read/38498097/effects-of-dapagliflozin-and-empagliflozin-on-6-min-walk-distance-in-heart-failure-with-preserved-and-reduced-ejection-fraction-a-systematic-review-and-meta-analysis-of-randomized-controlled-trials-involving-2624-patients
#22
REVIEW
Mohammad Tanashat, Almothana Manasrah, Mohamed Abouzid
BACKGROUND: Dapagliflozin and empagliflozin are antidiabetic medications. They are the first two sodium-glucose cotransporter-2 inhibitors (SGLT2i) to receive the US Food and Drug Administration approval to manage heart failure. Emerging new trials have examined changes in the 6-min walk distance as a clinically significant response to dapagliflozin and empagliflozin in patients with heart failure with reduced ejection fraction (HFpEF) and heart failure with preserved ejection fraction (HFrEF)...
March 18, 2024: European Journal of Clinical Pharmacology
https://read.qxmd.com/read/38483545/tyrosine-kinase-inhibitor-induced-hypothyroidism-mechanism-and-clinical-implications
#23
REVIEW
Zhipeng Wang, Hongsen Wang, Chen Bu, Bosu Meng, Yuhui Mu, Shouhong Gao, Wansheng Chen, Xia Tao
INTRODUCTION: Since the first experimentally proven tyrosine kinase inhibitor (TKI) imatinib was introduced in the clinical setting, TKIs have attracted widespread attention because of their remarkable therapeutic effects and improvement of survival rates. TKIs are small-molecule, multi-target, anti-cancer agents that target different tyrosine kinases and block downstream signaling. ADVERSE REACTIONS AND CONCERNS: However, with in-depth research on TKI drugs, the adverse reactions-for example, thyroid dysfunction-have become a concern and thus have attracted the attention of numerous researchers...
March 14, 2024: European Journal of Clinical Pharmacology
https://read.qxmd.com/read/38483544/pharmacokinetics-of-polymyxin-b-in-different-populations-a-systematic-review
#24
REVIEW
Xing Wang, Wenqiang Xiong, Maolian Zhong, Yan Liu, Yuqing Xiong, Xiaoyi Yi, Xiaosong Wang, Hong Zhang
BACKGROUND AND OBJECTIVES: Despite being clinically utilized for the treatment of infections, the limited therapeutic range of polymyxin B (PMB), along with considerable interpatient variability in its pharmacokinetics and frequent occurrence of acute kidney injury, has significantly hindered its widespread utilization. Recent research on the population pharmacokinetics of PMB has provided valuable insights. This study aims to review relevant literature to establish a theoretical foundation for individualized clinical management...
March 14, 2024: European Journal of Clinical Pharmacology
https://read.qxmd.com/read/38480637/chatgpt-for-generating-multiple-choice-questions-a-reply
#25
LETTER
Yavuz Selim Kıyak, Özlem Coşkun, Işıl İrem Budakoğlu, Canan Uluoğlu
No abstract text is available yet for this article.
March 14, 2024: European Journal of Clinical Pharmacology
https://read.qxmd.com/read/38478093/the-effect-of-concomitant-beta-blocker-use-on-survival-in-patients-with-metastatic-renal-cell-carcinoma-treated-with-a-vascular-endothelial-growth-factor-receptor-inhibitors-in-the-first-line
#26
JOURNAL ARTICLE
Mustafa Korkmaz, Melek Karakurt Eryılmaz, Mehmet Zahid Koçak, Muhammed Muhiddin Er, Engin Hendem, Aykut Demirkıran, Murat Araz, Mehmet Artaç
PURPOSE: Vascular endothelial growth factor (VEGF) inhibition is one of the cornerstones of treatment in the treatment of metastatic renal cell carcinoma (mRCC). Since RCC is a disease of advanced age and hypertension as a side effect of VEGF receptor inhibitors, beta-blocker use is common in these patients. We aimed to compare the treatment efficacy and survival results in case of concomitant use of these two drugs due to the inhibition of VEGF in beta-blockers. METHODS: A total of 121 patients with a diagnosis of mRCC who used sunitinib or pazopanib in first-line therapy were included in the study...
March 13, 2024: European Journal of Clinical Pharmacology
https://read.qxmd.com/read/38472389/real-world-characteristics-and-use-patterns-of-patients-treated-with-vericiguat-a-nationwide-longitudinal-cohort-study-in-germany
#27
JOURNAL ARTICLE
Fabian Kerwagen, Christoph Ohlmeier, Thomas Evers, Stefan Herrmann, Inga Bayh, Alexander Michel, Silvia Kruppert, Joanna Wilfer, Rolf Wachter, Michael Böhm, Stefan Störk
PURPOSE: Vericiguat reduced clinical endpoints in patients experiencing worsening heart failure in clinical trials, but its implementation outside trials is unclear. METHODS: This retrospective analysis of longitudinally collected data was based on the IQVIA™ LRx database, which includes ~ 80% of the prescriptions of the 73 million people covered by the German statutory health insurance. RESULTS: Between September 2021 and December 2022, vericiguat was initiated in 2916 adult patients...
March 12, 2024: European Journal of Clinical Pharmacology
https://read.qxmd.com/read/38466425/activities-of-clinical-pharmacologists-across-europe-a-survey-by-the-european-association-of-clinical-pharmacology-and-therapeutics
#28
JOURNAL ARTICLE
Pierre Marquet, Emilie Jouanjus, Joaquin Sáez-Peñataro, Aranzazu Sancho-Lopez
PURPOSE: In order to explore clinical pharmacology and therapeutics (CPT) teaching and practices across continental Europe, the European Association of Clinical Pharmacology and Therapeutics (EACPT) made a survey in 2022 amongst its 27 affiliated societies. METHODS: The survey was made available online to EACPT representatives, and 47 filled-in questionnaires were received from 25 countries (one to five per country), representing all geographic areas of Europe. RESULTS: Clinical pharmacologists (CPs) spend 25%, 30%, 15%, and 25% of their time in teaching, hospital activities, committees, and research, respectively, with large variations across and within countries...
March 11, 2024: European Journal of Clinical Pharmacology
https://read.qxmd.com/read/38441574/incidence-characteristics-and-risk-factors-of-drug-associated-muscle-adverse-reaction-a-retrospective-real-world-study-of-inpatients
#29
JOURNAL ARTICLE
Anqi Zhao, Daihong Guo, Man Zhu, Ao Gao, Peng Li, An Fu
OBJECTIVE: To analyze the clinical characteristics, incidence, and distribution of drug-associated muscle adverse reactions (DAMAR) in real-world inpatients, to provide valuable references for clinical medication use. METHODS: We conducted an automatic retrospective monitoring of inpatients from May 1, 2022, to April 30, 2023, to collect information on adverse drug reactions (ADR) of patients and conducted subsequent analyses. RESULTS: Among 102,430 hospitalizations, 1106 cases of DAMARs were identified, yielding an incidence of 1...
March 5, 2024: European Journal of Clinical Pharmacology
https://read.qxmd.com/read/38436704/impact-of-combined-propranolol-and-oxytocin-on-the-process-and-outcomes-of-labor-a-meta-analysis-of-randomized-controlled-trials
#30
JOURNAL ARTICLE
Xia Liu, Hai-Xu Chen, Bo Chen
PURPOSE: To systematically review the impact of propranolol combined with oxytocin on the process and outcomes of labor. METHODS: A comprehensive literature search was performed across multiple databases, including China National Knowledge Infrastructure (CNKI), VIP, Wanfang, China Biomedical Literature Database, PubMed, Embase, and the Cochrane Library. All publicly published randomized controlled trials (RCTs) of propranolol combined with oxytocin compared to the use of oxytocin alone in labor were collected...
March 4, 2024: European Journal of Clinical Pharmacology
https://read.qxmd.com/read/38430266/recommendations-for-the-safe-use-of-direct-oral-anticoagulants-in-patients-with-cirrhosis-based-on-a-systematic-review-of-pharmacokinetic-pharmacodynamic-and-safety-data
#31
REVIEW
Maaike M E Diesveld, Daniëlle W M Jacobs- Pijnenburg, Rianne A Weersink, Ina Barzel, Joost P H Drenth, Ton Lisman, Herold J Metselaar, Margje H Monster-Simons, Midas B Mulder, Eline Okel, Katja Taxis, Sander D Borgsteede
PURPOSE: The popularity of direct oral anticoagulants (DOACs) is increasing among patients with cirrhosis. Cirrhosis has a major impact on the pharmacokinetics of drugs, potentially increasing adverse events. Safe use of drugs in cirrhosis requires a diligent risk-benefit analysis. The aim of this study is to develop practice recommendations for safe use of DOACs in cirrhosis based on a systematic review of pharmacokinetic, pharmacodynamic and safety data. METHODS: We conducted a systematic literature search to identify studies on pharmacokinetics, pharmacodynamics and safety of DOACs in cirrhosis...
March 2, 2024: European Journal of Clinical Pharmacology
https://read.qxmd.com/read/38427083/evaluation-of-methods-measuring-medication-adherence-in-patients-with-polypharmacy-a-longitudinal-and-patient-perspective
#32
JOURNAL ARTICLE
Laura Mortelmans, Eva Goossens, Marjan De Graef, Jana Van Dingenen, Anne-Marie De Cock, Mirko Petrovic, Patricia van den Bemt, Tinne Dilles
PURPOSE: To explore patients' willingness to have medication adherence measured using different methods and evaluate the feasibility and validity of their combination (i.e., pill counts, a medication diary and a questionnaire assessing adherence two months post-discharge). METHODS: (1) A cross-sectional evaluation of the willingness of patients with polypharmacy to have their medication adherence measured post-discharge. (2) Medication adherence was monitored during two months using pill counts based on preserved medication packages and a diary in which patients registered their adherence-related problems...
March 1, 2024: European Journal of Clinical Pharmacology
https://read.qxmd.com/read/38421437/the-polymorphisms-of-candidate-pharmacokinetic-and-pharmacodynamic-genes-and-their-pharmacogenetic-impacts-on-the-effectiveness-of-risperidone-maintenance-therapy-among-saudi-children-with-autism
#33
JOURNAL ARTICLE
Sireen Abdul Rahim Shilbayeh, Iman Sharaf Adeen, Ayman Shawqi Alhazmi, Haya Aljurayb, Rana Saad Altokhais, Nourah Alhowaish, Khawlah Essa Aldilaijan, Mostafa Kamal, Anwar Mansour Alnakhli
BACKGROUND: Antipsychotics, including risperidone (RIS), are frequently indicated for various autism spectrum disorder (ASD) manifestations; however, "actionable" PGx testing in psychiatry regarding antipsychotic dosing and selection has limited applications in routine clinical practice because of the lack of standard guidelines, mostly due to the inconsistency and scarcity of genetic variant data. The current study is aimed at examining the association of RIS effectiveness, according to ABC-CV and CGI indexes, with relevant pharmacokinetics (PK) and pharmacodynamics (PD) genes...
February 29, 2024: European Journal of Clinical Pharmacology
https://read.qxmd.com/read/38421436/the-effects-of-drug-drug-interaction-on-linezolid-pharmacokinetics-a-systematic-review
#34
REVIEW
Qiang Xu, Yanlei Sang, Anna Gao, Lu Li
OBJECTIVES: Linezolid is a commonly used antibiotic in the clinical treatment of gram-positive bacterial infections. The impacts of drug interactions on the pharmacokinetics of linezolid are often overlooked. This manuscript aims to review the medications that affect the pharmacokinetics of linezolid. METHODS: In accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, we queried the PubMed, Embase, and Cochrane Library for publications from database establishment to November 3, 2023, using the search terms: "Linezolid" and "interaction," or "interact," or "drug-drug interaction," or "co-treatment," or "cotreatment," or "combined," or "combination...
February 29, 2024: European Journal of Clinical Pharmacology
https://read.qxmd.com/read/38416166/use-of-statins-and-risks-of-ovarian-uterine-and-cervical-diseases-a-cohort-study-in-the-uk-biobank
#35
JOURNAL ARTICLE
Xue-Feng Jiao, Hailong Li, Linan Zeng, Huazhen Yang, Yao Hu, Yuanyuan Qu, Wenwen Chen, Yajing Sun, Wei Zhang, Xiaoxi Zeng, Lingli Zhang
PURPOSE: To examine the associations between use of statins and risks of various ovarian, uterine, and cervical diseases, including ovarian cancer, endometrial cancer, cervical cancer, ovarian cyst, polycystic ovarian syndrome, endometriosis, endometrial hyperplasia, endometrial polyp, and cervical polyp. METHODS: We conducted a cohort study among female participants in the UK Biobank. Information on the use of statins was collected through verbal interview. Outcome information was obtained by linking to national cancer registry data and hospital inpatient data...
February 28, 2024: European Journal of Clinical Pharmacology
https://read.qxmd.com/read/38396309/dose-dependent-effect-of-lamotrigine-on-quetiapine-serum-concentration-in-patients-using-instant-release-tablets
#36
JOURNAL ARTICLE
Kristine Hole, Silje K Lorentsen, Karoline L Nordby, Marie Slettvik, Ida Tg Sørum, Espen Molden, Tore Haslemo
PURPOSE: Lamotrigine was previously reported to reduce serum concentration of quetiapine. The aim of this study was to investigate whether lamotrigine dose or quetiapine formulation was of importance for the drug interaction. METHODS: Patients combining lamotrigine with quetiapine (cases) were included retrospectively from a routine therapeutic drug monitoring (TDM) service, as were a control group of patients using quetiapine without any interacting drugs. The case and control groups were divided into groups using immediate release (IR) and extended release (XR) quetiapine...
February 23, 2024: European Journal of Clinical Pharmacology
https://read.qxmd.com/read/38396308/long-acting-b-2-agonists-laba-or-long-acting-muscarinic-antagonists-lama-which-one-may-be-the-first-option-in-group-a-copd-patients
#37
JOURNAL ARTICLE
Onur Turan, Nalan Ogan, Fulsen Bozkus, Nurhan Sarıoğlu, Pakize Ayşe Turan, Celal Satıcı
INTRODUCTION: Long-acting muscarinic antagonists (LAMA) or beta-2 agonists (LABA) have been recommended for symptom control in group A COPD patients as a first-line bronchodilator treatment in GOLD guidelines. However, there is no mention of priority/superiority between the two treatment options. We aimed to compare the effectiveness of these treatments in this group. METHODS: The study cohort was formed of all subjects from six pulmonology clinics with an initial diagnosis of COPD who were new users of a LAMA or LABA from January 2020 to December 2021...
February 23, 2024: European Journal of Clinical Pharmacology
https://read.qxmd.com/read/38386021/dahos-study-efficacy-of-dapagliflozin-in-treating-heart-failure-with-reduced-ejection-fraction-and-obstructive-sleep-apnea-syndrome-a-3-month-multicenter-randomized-controlled-clinical-trial
#38
JOURNAL ARTICLE
Liang Xie, Shengnan Li, Xiaojin Yu, Qin Wei, Fuchao Yu, Jiayi Tong
BACKGROUND: The recent discovery of new therapeutic approaches to heart failure with reduced ejection fraction (HFrEF), including sodium-glucose cotransporter-2 (SGLT-2) inhibitors, as well as improved treatment of co-morbidities has provided much needed help to HFrEF. In addition, dapagliflozin, one of the SGLT-2 inhibitors, serves as a promising candidate in treating obstructive sleep apnea (OSA) of HFrEF patients due to its likely mechanism of countering the pathophysiology of OSA of HFrEF...
February 22, 2024: European Journal of Clinical Pharmacology
https://read.qxmd.com/read/38372756/immune-related-serious-adverse-events-with-immune-checkpoint-inhibitors-systematic-review-and-network-meta-analysis
#39
REVIEW
Clara Oliveira, Beatrice Mainoli, Gonçalo S Duarte, Tiago Machado, Rita G Tinoco, Miguel Esperança-Martins, Joaquim J Ferreira, João Costa
PURPOSE: Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment, though uncertainty exists regarding their immune-related safety. The objective of this study was to assess the comparative safety profile (odds ratio) of ICIs and estimate the absolute rate of immune-related serious adverse events (irSAEs) in cancer patients undergoing treatment with ICIs. METHODS: We searched for randomized trials till February 2021, including all ICIs for all cancers...
February 19, 2024: European Journal of Clinical Pharmacology
https://read.qxmd.com/read/38367045/a-review-of-an-investigational-drug-retatrutide-a-novel-triple-agonist-agent-for-the-treatment-of-obesity
#40
REVIEW
Manmeet Kaur, Saurav Misra
BACKGROUND: Obesity is one of the critical public health problems in our society. It leads to various health conditions, such as type 2 diabetes mellitus, cardiovascular disease, hypertension, dyslipidaemia, and non-alcoholic fatty liver disease. With the rising incidence of obesity, there is a growing demand for new therapies which can effectively manage body weight and improve health. CURRENT EVIDENCE: Currently under development, multi-receptor agonist drugs may offer a promising solution to meet this unmet medical need...
February 17, 2024: European Journal of Clinical Pharmacology
journal
journal
25237
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.